BACKGROUND: Being overweight or obese is associated with increased breast cancer risk and disease severity among postmenopausal women, but whether extent of mammography use and accuracy modify this association and further contribute to increases in disease severity at diagnosis among overweight and obese women is unclear. METHODS: We prospectively collected data during 1996-2005 on 287,115 postmenopausal women not using hormone therapy (HT) who underwent 614,562 mammography examinations; 4,446 women were diagnosed with breast cancer within 12 months of a mammography examination. We calculated rates per 1,000 mammography examinations of large (>15 mm), advanced-stage (IIb, III, or IV), high-grade (3 or 4), estrogen receptor (ER)-positive and -negative, and screen-detected and non-screen-detected breast cancer across body mass index (BMI, kg/m(2)) groups defined as normal (18.5-24.9), overweight (25.0-29.9), obese class I (30.0-34.9), and obese class II/III (> or =35.0), adjusting for age, race/ethnicity, and mammography registry and use. All statistical tests were two-sided. RESULTS: Adjusted rates per 1000 mammography examinations of overall breast cancer increased across BMI groups (6.6 normal, 7.4 overweight, 7.9 obese I, 8.5 obese II/III; P(trend) < .001), as did rates of advanced disease, including large invasive (2.3 normal, 2.6 overweight, 2.9 obese I, 3.2 obese II/III; P(trend) < .001), advanced-stage (0.8 normal, 0.9 overweight, 1.3 obese I, 1.5 obese II/III; P(trend) < .001), and high nuclear grade (1.5 normal, 1.7 overweight, 1.7 obese I, 1.9 obese II/III; P(trend) = .10) tumors. Rates of ER-positive tumors increased across BMI groups (P(trend) < .001); rates of ER-negative tumors did not. Rates of screen-detected cancers were higher among overweight and obese women than normal and underweight women, but rates of non-screen-detected (false-negative) cancers were similar. Rates of advanced breast cancer increased across BMI groups regardless of extent of mammography use. CONCLUSIONS: Patterns of mammography use and mammography accuracy are not the primary reasons for higher rates of advanced breast cancer among overweight and obese postmenopausal women not using HT; thus, biologic differences in breast tumor development and/or progression may be important.
BACKGROUND: Being overweight or obese is associated with increased breast cancer risk and disease severity among postmenopausal women, but whether extent of mammography use and accuracy modify this association and further contribute to increases in disease severity at diagnosis among overweight and obesewomen is unclear. METHODS: We prospectively collected data during 1996-2005 on 287,115 postmenopausal women not using hormone therapy (HT) who underwent 614,562 mammography examinations; 4,446 women were diagnosed with breast cancer within 12 months of a mammography examination. We calculated rates per 1,000 mammography examinations of large (>15 mm), advanced-stage (IIb, III, or IV), high-grade (3 or 4), estrogen receptor (ER)-positive and -negative, and screen-detected and non-screen-detected breast cancer across body mass index (BMI, kg/m(2)) groups defined as normal (18.5-24.9), overweight (25.0-29.9), obese class I (30.0-34.9), and obese class II/III (> or =35.0), adjusting for age, race/ethnicity, and mammography registry and use. All statistical tests were two-sided. RESULTS: Adjusted rates per 1000 mammography examinations of overall breast cancer increased across BMI groups (6.6 normal, 7.4 overweight, 7.9 obese I, 8.5 obese II/III; P(trend) < .001), as did rates of advanced disease, including large invasive (2.3 normal, 2.6 overweight, 2.9 obese I, 3.2 obese II/III; P(trend) < .001), advanced-stage (0.8 normal, 0.9 overweight, 1.3 obese I, 1.5 obese II/III; P(trend) < .001), and high nuclear grade (1.5 normal, 1.7 overweight, 1.7 obese I, 1.9 obese II/III; P(trend) = .10) tumors. Rates of ER-positive tumors increased across BMI groups (P(trend) < .001); rates of ER-negative tumors did not. Rates of screen-detected cancers were higher among overweight and obesewomen than normal and underweight women, but rates of non-screen-detected (false-negative) cancers were similar. Rates of advanced breast cancer increased across BMI groups regardless of extent of mammography use. CONCLUSIONS: Patterns of mammography use and mammography accuracy are not the primary reasons for higher rates of advanced breast cancer among overweight and obese postmenopausal women not using HT; thus, biologic differences in breast tumor development and/or progression may be important.
Authors: Norman F Boyd; Lisa J Martin; Limei Sun; Helen Guo; Anna Chiarelli; Greg Hislop; Martin Yaffe; Salomon Minkin Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-11 Impact factor: 4.254
Authors: Jiyoung Ahn; Arthur Schatzkin; James V Lacey; Demetrius Albanes; Rachel Ballard-Barbash; Kenneth F Adams; Victor Kipnis; Traci Mouw; Albert R Hollenbeck; Michael F Leitzmann Journal: Arch Intern Med Date: 2007-10-22
Authors: A Heather Eliassen; Graham A Colditz; Bernard Rosner; Walter C Willett; Susan E Hankinson Journal: JAMA Date: 2006-07-12 Impact factor: 56.272
Authors: Heather Spencer Feigelson; Alpa V Patel; Lauren R Teras; Ted Gansler; Michael J Thun; Eugenia E Calle Journal: Cancer Date: 2006-07-01 Impact factor: 6.860
Authors: Anne E Cust; Tanja Stocks; Annekatrin Lukanova; Eva Lundin; Göran Hallmans; Rudolf Kaaks; Håkan Jonsson; Pär Stattin Journal: Breast Cancer Res Treat Date: 2008-03-11 Impact factor: 4.872
Authors: Karla Kerlikowske; Diana L Miglioretti; Diana S M Buist; Rod Walker; Patricia A Carney Journal: J Natl Cancer Inst Date: 2007-08-14 Impact factor: 13.506
Authors: Ellen A Schur; Joann E Elmore; Tracy Onega; Karen J Wernli; Edward A Sickles; Sebastien Haneuse Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-12-05 Impact factor: 4.254
Authors: Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Karla Kerlikowske; Charlotte C Gard; Jeffrey A Tice; Elad Ziv; Steven R Cummings; Diana L Miglioretti Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Amanda I Phipps; Diana S M Buist; Kathleen E Malone; William E Barlow; Peggy L Porter; Karla Kerlikowske; Ellen S O'Meara; Christopher I Li Journal: Ann Epidemiol Date: 2012-02-25 Impact factor: 3.797
Authors: Diana L Miglioretti; Jane Lange; Jeroen J van den Broek; Christoph I Lee; Nicolien T van Ravesteyn; Dominique Ritley; Karla Kerlikowske; Joshua J Fenton; Joy Melnikow; Harry J de Koning; Rebecca A Hubbard Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Shagufta Yasmeen; Rebecca A Hubbard; Patrick S Romano; Weiwei Zhu; Berta M Geller; Tracy Onega; Bonnie C Yankaskas; Diana L Miglioretti; Karla Kerlikowske Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-28 Impact factor: 4.254
Authors: Thomas P Ahern; Brian L Sprague; Michael C S Bissell; Diana L Miglioretti; Diana S M Buist; Dejana Braithwaite; Karla Kerlikowske Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-01-17 Impact factor: 4.254
Authors: Gretchen L Gierach; Laura Ichikawa; Karla Kerlikowske; Louise A Brinton; Ghada N Farhat; Pamela M Vacek; Donald L Weaver; Catherine Schairer; Stephen H Taplin; Mark E Sherman Journal: J Natl Cancer Inst Date: 2012-08-21 Impact factor: 13.506
Authors: Lesley A Stead; Timothy L Lash; Jerome E Sobieraj; Dorcas D Chi; Jennifer L Westrup; Marjory Charlot; Rita A Blanchard; John C Lee; Thomas C King; Carol L Rosenberg Journal: Breast Cancer Res Date: 2009-03-25 Impact factor: 6.466